![Urgent FDA Action Turns Power Morcellation Into Rarely Used Gynecological Procedure](https://cdn.cancerletter.com/media/2024/01/01031934/40-45-power-morcellation.jpg)
![Urgent FDA Action Turns Power Morcellation Into Rarely Used Gynecological Procedure](https://cdn.cancerletter.com/media/2024/01/01031934/40-45-power-morcellation.jpg)
Cover Story
Free
The power morcellator should no longer be used for hysterectomies or fibroid removal in the vast majority of women getting these procedures, FDA declared in a highly anticipated guidance document Nov. 24.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Drugs & Targets
Trending Stories
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement. - At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago
- The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop